Antibiotics for treatment and prevention ofexacerbations of chronic obstructive pulmonary disease

Journal of Infection

Volumn 67, Issue 6, 2013, Pages 497-515

  Wilson, Robert ^a   Sethi, Sanjay ^b   Anzueto, Antonio ^c   Miravitlles, Marc ^d  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Acute bacterial exacerbation of COPD; Antibiotics; Chronic inflammation; Fluoroquinolones; Inhalation therapy; Long term outcome; Macrolides

Indexed keywords

AMIKACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; AZTREONAM; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CIPROFLOXACIN; CLARITHROMYCIN; COLISTIN; CORTICOSTEROID; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; GEMIFLOXACIN; GENTAMICIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PLACEBO; TOBRAMYCIN; VANCOMYCIN;

ABDOMINAL PAIN; ACUTE DRUG ADMINISTRATION; ACUTE EXACERBATION; BACTERIAL INFECTION; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEARING DISORDER; HEARING IMPAIRMENT; HEART FAILURE; HUMAN; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; PROGNOSIS; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ACUTE BACTERIAL EXACERBATION OF COPD; ANTIBIOTICS; CHRONIC INFLAMMATION; FLUOROQUINOLONES; INHALATION THERAPY; LONG-TERM OUTCOME; MACROLIDES;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTIONS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 84887017757     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2013.08.010     Document Type: Review

References (124)

1. Mannino D.M., Buist A.S. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007, 370:765-773.
2. NHLBI Chronic obstructive pulmonary disease data fact sheet 2003, 03-5229, NIH Publication.
3. Global surveillance, prevention and control of chronic respiratory diseases. A comprehensive approach 2007, WHO. http://www.who.int/respiratory/publications/global_surveillance/en/index.html.
4. Tan W.C., Ng T.P. COPD in Asia: where east meets west. Chest 2008, 133:517-527.
5. Hurst J.R., Vestbo J., Anzueto A., Locantore N., Müllerova H., Tal-Singer R., et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010, 16:1128-1138.
6. Sialer S., Adamantia L., Guerrero M., Torres A. Relation between chronic obstructive pulmonary disease and antibiotics. Curr Infect Dis Rep 2012, 14:300-307.
7. Suissa S., Dell'Aniello S., Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 2012, 67:957-963.
8. Soler-Cataluna J.J., Martinez-Garcia M.A., Roman Sanchez P., Salcedo E., Navarro M., Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005, 60:925-931.
9. Spencer S., Jones P.W. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003, 58:589-593. GLOBE Study Group.
10. Miravitlles M., Murio C., Guerrero T., Gisbert R. Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest 2003, 123:784-791.
11. Burge P.S., Calverley P.M., Jones P.W., Spencer S., Anderson J.A., Maslen T.K. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000, 320(7245):1297-1303.
12. Calverley P.M., Boonsawat W., Cseke Z., Zhong N., Peterson S., Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003, 22:912-919.
13. Calverley P.M., Anderson J.A., Celli B., Ferguson G.T., Jenkins C., Jones P.W., et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356:775-789.
14. Tashkin D.P., Celli B., Senn S., Burkhart D., Kesten S., Menjoge S., et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359:1543-1554. UPLIFT Study Investigators.
15. Sethi S., Murphy T.F. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008, 359:2355-2365.
16. Wilson R. Treatment of COPD exacerbations: antibiotics. Eur Respir Rev 2005, 14:32-38.
17. Miravitlles M., Kruesmann F., Haverstock D., Perroncel R., Choudhri S.H., Arvis P. Sputum colour and bacteria in chronic bronchitis exacerbations: a pooled analysis. Eur Resp J 2012, 39:1354-1360.
18. Anthonisen N.R., Manfreda J., Warren C.P., Hershfield E.S., Harding G.K., Nelson N.A. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987, 106:196-204.
19. O'Donnell D.E., Hernandez P., Kaplan A., Aaron S., Bourbeau J., Marciniuk D., et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2008 update - highlights for primary care. Can Respir J 2008, 15(Suppl. A):1A-8A.
20. GOLD Global strategy for the diagnosis, management and prevention of COPD 2011, Global Initiative for Chronic Obstructive Lung Disease (GOLD), Available from:. http://www.goldcopd.org/uploads/users/files/GOLD_Report_2011_Feb21.pdf.
21. Woodhead M., Blasi F., Ewig S., Garau J., Huchon G., Ieven M., et al. Guidelines for the management of adult lower respiratory tract infections - full version. Clin Mirobiol Infect 2011, 17(Suppl. 6):E1-E59.
22. Roede B.M., Bresser P., Prins J.M., Schellevis F., Verheij T.J., Bindels P.J. Reduced risk of next exacerbation and mortality associated with antibiotic use in COPD. Eur Respir J 2009, 33:282-288.
23. Adams S.G., Melo J., Luther M., Anzueto A. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 2000, 117:1345-1352.
24. Aaron S.D., Vandemheen K.L., Hebert P., Dales R., Stiell I.G., Ahuja J., et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med 2003, 348:2618-2625.
25. White A.J., Gompertz S., Bayley D.L., Hill S.L., O'Brien C., Unsal I., et al. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax 2003, 58:680-685.
26. Daniels J.M.A., Snijders D., de Graaff C.S., Vlaspolder F., Jansen H.M., Boersma W.G. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010, 181:150-157.
27. Llor C., Moragas A., Hemández S., Bayona C., Miravitlles M. Efficacy of antibiotic therapy for acute exacerbations of mild to moderate COPD. Am J Respir Crit Care Med 2012, 186:716-723.
28. Wilson R., Anzueto A., Miravitlles M., Arvis P., Alder J., Haverstock D., et al. Moxifloxacin vs amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. Eur Respir J 2012, 40:17-27.
29. Wedzicha J.A., Seemungal T.A. COPD exacerbations: defining their cause and prevention. Lancet 2007, 370:786-796.
30. Hurst J.R., Donaldson G.C., Quint J.K., Goldring J.J., Baghai-Ravary R., Wedzicha J.A. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009, 179:369-374.
31. Wilson R., Schentag J.J., Ball P., Mandell L. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther 2002, 24:639-652. 068 Study Group.
32. Perera W.R., Hurst J.R., Wilkinson T.M.A., Sapsford R.J., Müllerova H., Donaldson G.C., et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J 2007, 29:527-534.
33. Sethi S., Evans N., Grant B.J., Murphy T.F. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002, 347:465-471.
34. Sethi S. Infection as a comorbidity of COPD. Eur Respir J 2010, 35:1209-1215.
35. Patel I.S., Seemungal T.A.R., Wilks M., Lloyd-Owen S.J., Donaldson G.C., Wedzicha J.A. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002, 57:759-764.
36. Banerjee D., Khair O.A., Honeybourne D. Impact of sputum bacteria on airway inflammation and health status in clinical stable COPD. Eur Respir J 2004, 23:685-691.
37. Wilkinson T.M., Patel I.S., Wilks M., Donaldson G.C., Wedzicha J.A. Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003, 167:1090-1095.
38. Sethi S., Maloney J., Grove L., Wrona C., Berenson C.S. Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 173:991-998.
39. Marin A., Garcia-Aymerich J., Sauleda J., Belda J., Millares L., García-Núñez M., et al. Effect of bronchial colonisation on airway and systemic inflammation in stable COPD. COPD 2012, 9:121-130.
40. Matkovic Z., Miravitlles M. Chronic bronchial infection in COPD. Is there an infective phenotype?. Resp Med 2013, 107:10-22.
41. Martínez-García M.Á., Soler-Cataluña J.J., Donat Sanz Y., Catalán Serra P., Agramunt Lerma M., Ballestín Vicente J., et al. Factors associated with bronchiectasis in patients with COPD. Chest 2011, 140:1130-1137.
42. Remy-Jardin M., Amara A., Campistron P., Mastora I., Delannoy V., Duhamel A., et al. Diagnosis of bronchiectasis with multislice spiral CT: accuracy of 3-mm-thick structured sections. Eur Radiol 2003, 13:1165-1171.
43. Miszkiel K.A., Wells A.U., Rubens M.B., Cole P.J., Hansell D.M. Effects of airway infection by Pseudomonas aeruginosa: a computed tomographic study. Thorax 1997, 52:260-264.
44. Paone G., Conti V., Vestri A., Leone A., Puglisi G., Benassi F., et al. Analysis of sputum markers in the evaluation of lung inflammation and functional impairment in symptomatic smokers and COPD patients. Dis Markers 2011, 31:91-100.
45. Albert R.K., Connett J., Bailey W.C., Casaburi R., Cooper J.A., Criner G.J., et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011, 365:689-698.
46. Sethi S., Jones P.W., Theron M.S., Miravitlles M., Rubinstein E., Wedzicha J.A., et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res 2010, 11:10.
47. Nouira S., Marghli S., Belghith M., Besbes L., Elatrous S., Abroug F. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet 2001, 358:2020-2025.
48. Allegra L., Blasi F., de Bernardi B., Cosentini R., Tarsia P. Antibiotic treatment and baseline severity of disease in acute exacerbations of chronic bronchitis: a re-evaluation of previously published data of a placebo-controlled randomized study. Pulm Pharmacol Ther 2001, 14:149-155.
49. Allegra L., Konietzko N., Leophonte P., Hosie J., Pauwels R., Guyen J.N., et al. Comparative safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a double-blind, randomised, parallel, multicentre study. J Antimicrob Chemother 1996, 27(Suppl. A):93-104.
50. Bandak S.I., Bolzon L.D., Turnak M.R., Johns D., Henle S.K., Allen B.S. Cefaclor versus amoxicillin/clavulanate in acute bacterial exacerbations of chronic bronchitis: a randomised multicentre study. Int J Clin Pract 1999, 53:578-583.
51. Chodosh S., DeAbate C.A., Haverstock D., Aneiro L., Church D. Short course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. Resp Med 2000, 94:18-27. The Bronchitis Study Group.
52. DeAbate C.A., Mathew C.P., Warner J.H., Heyd A., Church D. The safety and efficacy of short course (5 day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbations of chronic bronchitis. Resp Med 2000, 94:1029-1037.
53. Weiss L.R. Open-label, randomized comparison of clarithromycin, levofloxacin and cefuroxime axetil in the treatment of adults with acute bacterial exacerbations of chronic bronchitis. Clin Ther 2002, 24:1414-1424.
54. Urueta-Robledo J., Ariza H., Jardim J.R., Caballero A., García-Calderón A., Amábile-Cuevas C.F., et al. Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronchitis: the Latine American cohort. Respir Med 2006, 100:1504-1511.
55. Wilson R., Allegra L., Huchon G., Izquierdo J.L., Jones P., Schaberg T., et al. Short and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004, 125:953-964.
56. Grassi C., Casali L., Curti E., Tellarini M., Lazzaro C., Schito G. Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB). J Chemother 2002, 14:597-608. SMART Study Group, Studio Multicentrico con Moxifloxacina nel Trattamento delle Riacutizzazioni de Bronchite CronicaStudio Multicentrico con Moxifloxacina nel Trattamento delle Riacutizzazioni de Bronchite Cronica.
57. Petitpretz P., Chone C., Tremolieres F. Levofloxacin 500mg once daily versus cefuroxime 250mg twice daily in patients with acute exacerbations of chronic obstructive bronchitits: clinical efficacy and exacerbation-free interval. Int J Antimicrob Agents 2007, 30:52-59. Investigator Study Group.
58. Ruiz-Gonzalez A., Gimenez A., Gomez-Arbones X., Soler-González J., Sánchez V., Falguera M., et al. Open-label, randomized comparison trial of long-term outcomes of levofloxacin versus standard antibiotic therapy in acute exacerbations of chronic obstructive pulmonary disease. Respirology 2007, 12:117-121.
59. Lode H., Eller J., Linnhoff A., Ioanas M. Evaluation of therapy-free interval in COPD patients study group. Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval. Eur Respir J 2004, 24:947-953.
60. Chodosh S., Schreurs A., Siami G., Barkman H.W., Anzueto A., Shan M., et al. Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. Clin Infect Dis 1998, 27:730-738.
61. Nouira S., Marghli S., Besbes L., Boukef R., Daami M., Nciri N., et al. Standard versus newer antibacterial agents in the treatment of severe acute exacerbation of chronic obstructive pulmonary disease; a randomised trial of trimethoprim-sulfamethoxazole versus ciprofloxacin. Clin Infect Dis 2010, 51:143-149.
62. Snoeck-Stroband J.B., Lapperre T.S., Gosman M.M.E., Boezen H.M., Timens W., ten Hacken N.H., et al. Chronic bronchitis sub-phenotype within COPD: inflammation in sputum and biopsies. Eur Respir J 2008, 31:70-77.
63. Gompertz S., O'Brien C., Bayley D.L., Hill S.L., Stockley R.A. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J 2001, 17:1112-1119.
64. Zhu J., Qiu Y.S., Majumdar S., Gamble E., Matin D., Turato G., et al. Exacerbations of bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants. Am J Respir Crit Care Med 2001, 164:109-116.
65. Sethi S. New developments in the pathogenesis of acute exacerbations of chronic obstructive pulmonary disease. Curr Opin Infect Dis 2004, 17:113-139.
66. Papi A., Bellettato C.M., Braccioni F., Romagnoli M., Casolari P., Caramori G., et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006, 173:1114-1121.
67. Ramsey B., Pepe M.S., Quan J.M., Otto K.L., Montgomery A.B., Williams-Warren J., et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999, 340:23-30. Cystic Fibrosis Inhaled Tobramycin Study Group.
68. Murphy T.D., Anbar R.D., Lester L.A., Nasr S.Z., Nickerson B., VanDevanter D.R., et al. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr Pulmonol 2004, 38:314-320.
69. Stead R.J., Hodson M.E., Batten J.C. Inhaled ceftazidime compared with gentamicin and carbenicillin in older patients with cystic fibrosis infected with Pseudomonas aeruginosa. Br J Dis Chest 1987, 81:272-279.
70. Jensen T., Pedersen S.S., Garne S., Heilmann C., Høiby N., Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987, 19:831-838.
71. Schaad U.B., Wedgwood J., Ruedeberg A., Kraemer R., Hampel B. Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis. Pediatr Infect Dis J 1997, 16:106-111.
72. Murray M.P., Govan J.R., Doherty C.J., Simpson A.J., Wilkinson T.S., Chalmers J.D., et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011, 183:491-499.
73. Kudoh S., Azuma A., Yamamoto M., Izumi T., Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 1998, 157:1829-1832.
74. Hashiba M., Baba S. Efficacy of long-term administration of clarithromycin in the treatment of intractable chronic sinusitis. Acta Otolaryngol Suppl 1996, 525:73-78.
75. Cervin A., Kalm O., Sandkull P., Lindberg S. One-year low-dose erythromycin treatment of persistent chronic sinusitis after sinus surgery: clinical outcome and effects on mucociliary parameters and nasal nitric oxide. Otolaryngol Head Neck Surg 2002, 126:481-489.
76. Cymbala A.A., Edmonds L.C., Bauer M.A., Jederlinic P.J., May J.J., Victory J.M., et al. The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. Treat Respir Med 2005, 4:117-122.
77. Serisier D.J., Martin M.L. Long-term, low-dose erythromycin in bronchiectasis subjects with frequent infective exacerbations. Respir Med 2011, 105:946-949.
78. Wong C., Jayaram L., Karalus N., Eaton T., Tong C., Hockey H., et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012, 380:660-667.
79. Staykova T., Black P., Staykova T., Chacko E., Poole P. Prophylactic antibiotic therapy for chronic bronchitis. Cochrane Database Syst Rev 2003, (1):CD004105.
80. Milstone A.P. Use of azithromycin in the treatment of acute exacerbations of COPD. Int J COPD 2008, 3:515-520.
81. Suzuki T., Yanai M., Yamaya M., Satoh-Nakagawa T., Sekizawa K., Ishida S., et al. Erythromycin and common cold in COPD. Chest 2001, 120:730-733.
82. Banerjee D., Honeybourne D., Khair O.A. The effect of oral clarithromycin on bronchial airway inflammation in moderate-to-severe stable COPD: a randomized controlled trial. Treat Respir Med 2004, 3:59-65.
83. Blasi F., Bonardi D., Aliberti S., Tarsia P., Confalonieri M., Amir O., et al. Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy. Pulmon Phamacol Ther 2010, 23:200-207.
84. He Z.-Y., Ou L.-M., Zhang J.-Q., Bai J., Liu G.N., Li M.H., et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pulmonary disease. Respiration 2010, 80:445-452.
85. Pomares X., Montón C., Espasa M., Casabon J., Monsó E., Gallego M. Long-term azithromycin therapy in patients with severe COPD and repeated exacerbations. Int J COPD 2011, 6:449-456.
86. Seemungal T.A., Wilkinson T.M., Hurst J.R., Perera W.R., Sapsford R.J., Wedzicha J.A. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008, 178:1139-1147.
87. Crosbie P.A., Woodhead M.A. Long-term macrolide therapy in chronic inflammatory airway diseases. Eur Respir J 2009, 33:171-181.
88. Miravitlles M., Marín A., Monsó E., Vilà S., de la Roza C., Hervás R., et al. Efficacy of moxifloxacin in the treatment of bronchial colonisation in COPD. Eur Respir J 2009, 34:1066-1071.
89. Ray W.A., Murray K.T., Hall K., Arbogast P.G., Stein C.M. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012, 366:1881-1890.
90. Miravitlles M., Soler-Cataluña J.J., Calle M., Molina J., Almagro P., Quintano J.A., et al. Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Arch Bronconeumol 2012, 48:247-257.
91. Wilson R., Welte T., Polverino E., De Soyza A., Greville H., O'Donnell A., et al. Ciprofloxacin DPI in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Resp J 2013, 41:1107-1115.
92. Drobnic M.E., Suñé P., Montoro J.B., Ferrer A., Orriols R. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005, 39:39-44.
93. Fiel S. Aerosolized antibiotics in cystic fibrosis: current and future trends. Exp Rev Resp Med 2008, 2:479-487.
94. Couch L.A. Treatment with tobramycin solution for inhalation in bronchiectasis patients with Pseudomonas aeruginosa. Chest 2001, 120(Suppl. 3):114S-117S.
95. Bilton D., Henig N., Morrissey B., Gotfried M. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 2006, 130:1503-1510.
96. Diot P., Dequin P.F., Rivoire B., Gagnadoux F., Faurisson F., Diot E., et al. Aerosols and anti-infectious agents. J Aerosol Med 2001, 14:55-64.
97. Kuhn R. Formulation of aerosolized therapeutics. Chest 2001, 120:945-985.
98. Hagerman J.K., Hancock K.E., Klepser M.E. Aerosolised antibiotics: a critical appraisal of their use. Expert Opin Drug Deliv 2006, 3:71-86.
99. Klastersky J., Huysmans E., Weerts D., Hensgens C., Daneau D. Endotracheally administered gentamicin for the prevention of infections of the respiratory tract in patients with tracheostomy: a double-blind study. Chest 1974, 65:650-654.
100. Klastersky J., Carpentier-Meunier F., Kahan-Coppens L., Thys J.P. Endotracheally administered antibiotics for gram-negative bronchopneumonia. Chest 1979, 75:586-591.
101. Brown R.B., Kruse J.A., Counts G.W., Russell J.A., Christou N.V., Sands M.L. Double-blind study of endotracheal tobramycin in the treatment of gram-negative bacterial pneumonia. Antimicrob Agents Chemother 1990, 34:269-272. The Endotracheal Tobramycin Study Group.
102. Palmer L.B., Smaldone G.C., Simon S.R., O'Riordan T.G., Cuccia A. Aerosolized antibiotics in mechanically ventilated patients: delivery and response. Crit Care Med 1998, 26:31-39.
103. Elman M., Goldstein I., Marquette C.H., Wallet F., Lenaour G., Rouby J.J. Influence of lung aeration on pulmonary concentrations of nebulized and intravenous amikacin in ventilated piglets with severe bronchopneumonia. Anesthesiology 2002, 97:199-206. Experimental ICU Study Group.
104. Luyt C.E., Clavel M., Guntupalli K., Johannigman J., Kennedy J.I., Wood C., et al. Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia. Crit Care 2009, 13:R200.
105. Griese M., Eismann C., Börner G., Denk O., Schierholz J.M., Keller M., et al. A pharmacokinetics and safety comparison of a highly concentrated tobramycin solution with TOBI. J Aerosol Med Pulm Drug Deliv 2013 Jun 22, [Epub ahead of print]. 10.1089/jamp.2012.1022.
106. Lenoir G., Antypkin Y.G., Miano A., Moretti P., Zanda M., Varoli G., et al. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Paediatr Drugs 2007, 9(Suppl. 1):11-20.
107. Chuchalin A., Csiszér E., Gyurkovics K., Bartnicka M.T., Sands D., Kapranov N., et al. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study. Paediatr Drugs 2007, 9(Suppl. 1):21-31.
108. McCoy K.S., Quittner A.L., Oermann C.M., Gibson R.L., Retsch-Bogart G.Z., Montgomery A.B. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008, 178:921-928.
109. Palmer L.B., Smaldone G.C., Chen J.J., Baram D., Duan T., Monteforte M., et al. Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit. Crit Care Med 2008, 36:2008-2013.
110. Hansen C.R., Pressler T., Høiby N. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros 2008, 7:523-530.
111. Retsch-Bogart G.Z., Quittner A.L., Gibson R.L., Oermann C.M., McCoy K.S., Montgomery A.B., et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 2009, 135:1223-1232.
112. Oermann C.M., McCoy K.S., Retsch-Bogart G.Z., Gibson R.L., McKevitt M., Montgomery A.B. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI). J Antimicrob Chemother 2011, 66:2398-2404.
113. Konstan M.W., Geller D.E., Minić P., Brockhaus F., Zhang J., Angyalosi G. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial. Pediatr Pulmonol 2010, 46:230-238.
114. Konstan M.W., Flume P.A., Kappler M., Chiron R., Higgins M., Brockhaus F., et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros 2011, 10:54-61.
115. Wainwright C.E., Quittner A.L., Geller D.E., Nakamura C., Wooldridge J.L., Gibson R.L., et al. Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa. J Cyst Fibros 2011, 10:234-242.
116. Clancy J.P., Dupont L., Konstan M.W., Billings J., Fustik S., Goss C.H., et al. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax 2013, 68:818-825. Arikace Study Group.
117. Dal Negro R., Micheletto C., Tognella S., Visconti M., Turati C. Tobramycin nebulizer solution in severe COPD patients colonized with Pseudomonas aeruginosa: effects on bronchial inflammation. Adv Ther 2008, 25:1019-1030.
118. Garcia-Vidal C., Almagro P., Romaní V., Rodríguez-Carballeira M., Cuchi E., Canales L., et al. Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study. Eur Respir J 2009, 34:1072-1078.
119. Davies G., Wells A.U., Doffman S., Watanabe S., Wilson R. The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis. Eur Respir J 2006, 28:974-979.
120. Sethi S., Rennard S.I., Miravitlles M., Martinez F.J., Donohue J.F., Anzueto A., et al. A Phase 2 study to evaluate the safety, tolerability and efficacy of levofloxacin inhalation solution (MP-376) administered for 5 days every 28 days to prevent acute exacerbations in high risk COPD patients. Am J Respir Crit Care Med 2012, 185:A3037.
121. Azoicai D., Antoniu S. MP-376 (Aeroquin) for chronic Pseudomonas aeruginosa infections. Expert Opin Investig Drugs 2013, 22:267-276.
122. Murphy T.F., Sethi S. Chronic obstructive pulmonary disease. Role of bacteria and guide to antibacterial selection in the older patient. Drugs Aging 2002, 19:761-775.
123. Dever L.L., Shashikumar K., Johanson W.G. Antibiotics in the treatment of acute exacerbations of chronic bronchitis. Expert Opin Investig Drugs 2002, 11:911-925.
124. Miravitlles M., Llor C. Determining factors in the prescription of moxifloxacin in exacerbations of chronic bronchitis in the primary-care setting. Clin Drug Invest 2007, 27:95-104.